Denis C. Guttridge

Denis C. Guttridge

Auto-generated profile, based on publicly available information

Denis C. Guttridge

Arthur G. James Comprehensive Cancer Center, The Ohio State University, Columbus, OH USA

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2008 in Cancer Cell
Verified
Journal Article
Closed access
HWHuating Wang
Huating Wang
RGRamiro Garzon
Ramiro Garzon
HSHao Sun
Hao Sun
KLKatherine J. Ladner
Katherine J. Ladner
RSRavi Singh
Ravi Singh
DGDenis C. Guttridge
Denis C. Guttridge

2 April 2007 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
SASwarnali Acharyya
Swarnali Acharyya
SVS. Armando Villalta
S. Armando Villalta
NBNadine Bakkar
Nadine Bakkar
TBTepmanas Bupha-Intr
Tepmanas Bupha-Intr
PJPaul Janssen
Paul Janssen
DGDenis C. Guttridge
Denis C. Guttridge
Duchenne muscular dystrophy (DMD) is a lethal X-linked disorder associated with dystrophin deficiency that results in chronic inflammation and severe skeletal muscle degeneration. In DMD mouse models and patients, we find that IκB kinase/NF-κB (IKK/NF-κB) signaling is persistently elevated in immune cells and regenerative muscle fibers. Ablation of 1 allele of the p65 subunit of NF-κB was sufficient to improve pathology in mdx mice, a model of DMD. In addition, conditional deletion of IKKβ in mdx mice elucidated that NF-κB functions in activated macrophages to promote inflammation and muscle necrosis and in skeletal muscle fibers to limit regeneration through the inhibition of muscle progenitor cells. Furthermore, specific pharmacological inhibition of IKK resulted in improved pathology and muscle function in mdx mice. Collectively, these results underscore the critical role of NF-κB in the progression of muscular dystrophy and suggest the IKK/NF-κB signaling pathway as a potential therapeutic target for DMD.

1 October 2013 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
WHWei A. He
Wei A. He
EBEmanuele Berardi
Emanuele Berardi
VCVeronica M. Cardillo
Veronica M. Cardillo
SASwarnali Acharyya
Swarnali Acharyya
PAPaola Aulino
Paola Aulino
DGDenis C. Guttridge
Denis C. Guttridge
Cachexia is a debilitating condition characterized by extreme skeletal muscle wasting that contributes significantly to morbidity and mortality. Efforts to elucidate the underlying mechanisms of muscle loss have predominantly focused on events intrinsic to the myofiber. In contrast, less regard has been given to potential contributory factors outside the fiber within the muscle microenvironment. In tumor-bearing mice and patients with pancreatic cancer, we found that cachexia was associated with a type of muscle damage resulting in activation of both satellite and nonsatellite muscle progenitor cells. These muscle progenitors committed to a myogenic program, but were inhibited from completing differentiation by an event linked with persistent expression of the self-renewing factor Pax7. Overexpression of Pax7 was sufficient to induce atrophy in normal muscle, while under tumor conditions, the reduction of Pax7 or exogenous addition of its downstream target, MyoD, reversed wasting by restoring cell differentiation and fusion with injured fibers. Furthermore, Pax7 was induced by serum factors from cachectic mice and patients, in an NF-κB–dependent manner, both in vitro and in vivo. Together, these results suggest that Pax7 responds to NF-κB by impairing the regenerative capacity of myogenic cells in the muscle microenvironment to drive muscle wasting in cancer.

1 November 2015 in Bone
Verified
Journal Article
Closed access
PLPriya Londhe
Priya Londhe
DGDenis C. Guttridge
Denis C. Guttridge

1 June 2007 in Molecular and Cellular Biology
Verified
Journal Article
Closed access
PDF file
HWHuating Wang
Huating Wang
EHErin Hertlein
Erin Hertlein
NBNadine Bakkar
Nadine Bakkar
HSHao Sun
Hao Sun
SASwarnali Acharyya
Swarnali Acharyya
DGDenis C. Guttridge
Denis C. Guttridge
NF-κB signaling is implicated as an important regulator of skeletal muscle homeostasis, but the mechanisms by which this transcription factor contributes to muscle maturation and turnover remain unclear. To gain insight into these mechanisms, gene expression profiling was examined in C2C12 myoblasts devoid of NF-κB activity. Interestingly, even in proliferating myoblasts, the absence of NF-κB caused the pronounced induction of several myofibrillar genes, suggesting that NF-κB functions as a negative regulator of late-stage muscle differentiation. Although several myofibrillar promoters contain predicted NF-κB binding sites, functional analysis using the troponin-I2 gene as a model revealed that NF-κB-mediated repression does not occur through direct DNA binding. In the search for an indirect mediator, the transcriptional repressor YinYang1 (YY1) was identified. While inducers of NF-κB stimulated YY1 expression in multiple cell types, genetic ablation of the RelA/p65 subunit of NF-κB in both cultured cells and adult skeletal muscle correlated with reduced YY1 transcripts and protein. NF-κB regulation of YY1 occurred at the transcriptional level, mediated by direct binding of the p50/p65 heterodimer complex to the YY1 promoter. Furthermore, YY1 was found associated with multiple myofibrillar promoters in C2C12 myoblasts containing NF-κB activity. Based on these results, we propose that NF-κB regulation of YY1 and transcriptional silencing of myofibrillar genes represent a new mechanism by which NF-κB functions in myoblasts to modulate skeletal muscle differentiation.

10 March 2014 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
WHWei A. He
Wei A. He
FCFederica Calore
Federica Calore
PLPriya Londhe
Priya Londhe
Alessandro CanellaAlessandro Canella
Alessandro Canella
DGDenis C. Guttridge
Denis C. Guttridge
CCCarlo Crocecarlo
Carlo Crocecarlo
MicroRNAs (miRNAs) are small, noncoding RNAs that regulate gene expression and, in cancers, are often packaged within secreted microvesicles. The cachexia syndrome is a debilitating state of cancer that predominantly results from the loss of skeletal muscle mass, which is in part associated with apoptosis. How tumors promote apoptosis in distally located skeletal muscles has not been explored. Using both tumor cell lines and patient samples, we show that tumor-derived microvesicles induce apoptosis of skeletal muscle cells. This proapoptotic activity is mediated by a microRNA cargo, miR-21, which signals through the Toll-like 7 receptor (TLR7) on murine myoblasts to promote cell death. Furthermore, tumor microvesicles and miR-21 require c-Jun N-terminal kinase activity to regulate this apoptotic response. Together, these results describe a unique pathway by which tumor cells promote muscle loss, which might provide a great insight into elucidating the causes and treatment options of cancer cachexia.